apfcbAPFCB eNewscoAPFCB News Volume 3, Issue 1MultidisciplinaryEnglishJan-Jun, 2024NNY20240517ArticlesNavigating Lp(a) Measurement Challenges: From Guidelines to Laboratory PerspectivesEnglishY8392Dr. Deepak NParchwani1EnglishNDr. Ragini D.1SinghEnglishYProf Dr (Col) CDSKatoch2EnglishY10.62772/APFCB-News.2024.1.2This comprehensive review delves into the evolving landscape of Lp(a) measurement standardsand examines the discordance and challenges in cardiovascular risk assessment in the contextof Lp(a). Acknowledging the shifting trends towards universal screening for Lp(a) endorsed by international societies working on risk assessment, management, and prevention of cardiovascular diseases, this review highlights the divergence in recommendations and the lackof consensus on Lp(a) risk thresholds. Ethnic variations in Lp(a) levels and ongoing clinical trial stargeting Lp(a) underscore the urgency of a unified and standardized approach to Lp(a) measurement. This article explores the intricacies of Lp(a) isoform size heterogeneity, availablemeasurement approaches, and the reporting unit challenge for the molecule. Emphasis is placed on collaborative efforts, transparent calibration, and the pivotal role of laboratories in ensuring the precision and reliability of Lp(a) measurements. The discussion encompasses thecall for unified calibration standards, highlighting the need for continuous external quality assessment and transparent reporting in clinical laboratories until a standardized Lp(a) measurement system is established.Englishhttps://apfcb.org/APFCB_News/abstract?id=2References16191. Alebna P L, Mehta A. An Update on Lipoprotein(a): The Latest on Testing, Treatment, and Guideline Recommendations. Expert Analysis, Sep 19, 20232. Virani SS, Koschinsky ML, Maher L, et al. Global think tank on the clinical considerationsand management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. Prog Cardiovasc Dis. 2022;73:32-40. doi:10.1016/j.pcad.2022.01.0023. Wei, Trent; Cho, Leslie. Recent lipoprotein(a) trials. Current Opinion in Lipidology 33(6):p 301-308, December 2022. | DOI: 10.1097/MOL.00000000000008564. Kronenberg F, Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013;273(1):6-30. https://doi.org/10.1111/j.1365-2796.2012.02592.x.5. Utermann G, Menzel HJ, Kraft HG, Duba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987;80(2):458-465. doi:10.1172/JCI1130936. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41(2):246-255.7. Cegla J, France M, Marcovina SM, Neely RDG. Lp(a): When and how to measure it. Ann Clin Biochem. 2021;58(1):16-21. doi:10.1177/00045632209684738. Kronenberg F, Tsimikas S. The challenges of measuring Lp(a): A fight against Hydra?. Atherosclerosis. 2019;289:181-183. doi:10.1016/j.atherosclerosis.2019.08.0199. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association [published correction appears in J Clin Lipidol. 2022 Sep-Oct;16(5):e77- e95]. J Clin Lipidol. 2019;13(3):374-392. doi:10.1016/j.jacl.2019.04.010 10. Mooser V, Marcovina SM, White AL, Hobbs HH. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J Clin Invest. 1996;98(10):2414-2424. doi:10.1172/JCI119055.11. Kostner KM, Maurer G, Huber K, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol. 1996;16(8):905-911. doi:10.1161/01.atv.16.8.90512. Marcovina SM, Clouet-Foraison N, Koschinsky ML, et al. Development of an LC-MS/ MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a). Clin Chem 2021;67(3):490-499. https://doi. org/10.1093/clinchem/hvaa32413. Benn M, Nordestgaard BG. From genome-wide association studies to Mendelian randomization: novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. Cardiovasc Res. 2018;114(9):1192-1208. doi:10.1093/cvr/cvy04514. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526-537. doi:10.1194/jlr.R06164815. Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. J Clin Lipidol. 2018;12(5):1313-1323. doi:10.1016/j.jacl.2018.07.00316. Kronenberg F. Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? Atherosclerosis. 2022;349:123-135. doi:10.1016/j.atherosclerosis.2022.04.00817. Scharnagl H, Stojakovic T, Dieplinger B, et al. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. Atherosclerosis. 2019;289:206-213. doi:10.1016/j.atherosclerosis.2019.08.01518. Cobbaert CM, Althaus H, Begcevic Brkovic I, et al. Towards an SI-Traceable Reference Measurement System for Seven Serum Apolipoproteins Using Bottom-Up Quantitative Proteomics: Conceptual Approach Enabled by Cross-Disciplinary/Cross-Sector Collaboration. Clin Chem. 2021;67(3):478-489. doi:10.1093/clinchem/hvaa239